All posts by imreal

Healthcare Veterans Launch AI-Driven Physician and Nurse Staffing Technology Venture, Polaris Health


SwitchPoint Ventures announced Tuesday the launch of Polaris Health, an AI-driven health IT company with an all-in-one solution that predicts provider demand volumes and produces optimal clinician schedules.

Predicting provider demand has long plagued healthcare administrators focused on cost reduction activities. In fact, according to a study by the Healthcare Financial Management Association, labor expense is the number one priority for hospital CFOs seeking to reduce operating expenses. 1

Polaris Health’s solution utilizes proprietary machine learning algorithms to predict provider demand, distribute clinician resources to meet that demand, and optimize clinician schedules. It caters to physicians and nurses alike and is applicable to any practice area or specialty.

SwitchPoint Ventures built Polaris Health’s core technology in collaboration with PhyMed Healthcare Group, the physician-led and owned anesthesia services leader, to address their desire to better optimize clinical staffing, both from a provider satisfaction and cost efficiency perspective.

“We are a forward looking, data-driven organization,” said PhyMed CEO Marty Bonick. “Although we use several labor management tools, there is no solution currently in the market that accurately predicts patient demand to inform our staffing needs. We partnered with SwitchPoint because of their expertise in exploring how AI could be leveraged to address our needs. We couldn’t be more impressed with the collaboration with the team and accuracy of the prediction models in creating something that no one has ever successfully done before.”

The resulting AI-powered technology developed through the PhyMed collaboration gave birth to Polaris Health.

Polaris Health will be led by Dr. Sam Clemmons, an emergency medicine physician who has more than 25 years of experience growing and leading operations for independent physician groups, including American Physicians Partners.

“When I was introduced to the Polaris technology, I knew I had to jump on board,” says Dr. Clemmons. “As a clinician, I have personally experienced the frustration of being given suboptimal schedules that don’t support a healthy work-life balance. As an operator, I understand the difficulty in balancing care coverage while containing costs.”

Dr. Clemmons and his team will continue to be backed by SwitchPoint Ventures, the venture studio led by healthcare data science veterans that launches artificial intelligence-powered businesses by pairing its expertise in AI with the industry expertise of respected organizations.

About Polaris Health:

Polaris exists to help healthcare providers deliver superior care in a sustainable model amid a complex, ever-changing environment. Through cutting-edge technologies, we will bring equilibrium to the healthcare labor market. For more information, please visit http://www.polarishealth.ai.

About PhyMed Healthcare:

Headquartered in Nashville Tennessee, PhyMed Healthcare Group is a physician-led and owned anesthesia services leader with a focus on redefining perioperative partnerships.  PhyMed clinicians create positive patient interactions before, during and after surgery as a trusted partner to healthcare systems, ambulatory surgery centers and office-based anesthesia with over 900 clinicians nationwide. Learn more at http://www.phymed.com.

About SwitchPoint Ventures:

SwitchPoint exists to help people and organizations achieve their highest potential through exploration, insight, and innovation. We partner with subject matter experts across industries who share our core values, embrace innovation, and strive for deep understanding of their respective domains. Within a partnership format, we create high-impact products and companies with artificial intelligence as a core component. Our vision is to become the most admired company advancing business through artificial intelligence. Learn more at http://www.switchpointventures.com.

1 HFMA & Navigant, Aug 2018

Share article on social media or email:

Psilera Bioscience Announces Award-Winning Executive Team and Flagship Patent Milestone for Future Psychedelic Therapies


We are only scratching the surface of the medical potential for psychedelics and Psilera’s model of compassion-driven science will enable groundbreaking research to provide new therapies for patients in need

Psilera Bioscience (“Psilera”), a Florida based biotechnology LLC specializing in the clinical development of psychedelics and analogues, announces its core executive team. The co-founders Drs. Jackie Salm and Chris Witowski have 20+ years combined experience in natural product drug discovery, novel formulations, and as distinguished researchers within the cannabis industry. They are joined by pharmaceutical and corporate leaders alongside an extensive network of scientific and medical advisors.

“Problems relating to mental health are a growing concern, and the hardships created by COVID-19 have only exacerbated issues with depression, anxiety, and substance abuse,” said Dr. Chris Witowski, CEO of Psilera. “Therapeutic innovations have stagnated in these areas while cognitive disorders such as Alzheimer’s disease also lack effective treatment options. We are only scratching the surface of the medical potential for psychedelics and Psilera’s model of compassion-driven science will enable groundbreaking research to provide new therapies for patients in need.”

Psilocybin, the psychoactive ingredient found in some mushroom species, acts on the serotonin system but unlike other antidepressants only a few doses are needed for long-term benefits. This finding will increase acceptance of psychotherapies, while their ability to disrupt preconditioned thinking and improve cognition will provide Psilera a significant clinical pipeline for future discoveries. Psilera has accelerated research and development efforts and submitted a provisional patent covering new chemical entities and delivery methods relating to psychedelics.

“Psilera was built with the common goal to create mindful medicine with inspirations from nature and a foundation of innovative science,” said Dr. Jackie Salm, CSO of Psilera. “Our goal is to pave the way for a new era in psychedelics research and truly recognize the potential of these compounds as medicines. This requires detailed assessment of structure activity relationships and novel ways of delivery. We hope to increase awareness and shift the paradigm to a place of knowledge rather than fear.”

About Psilera Bioscience

Psilera Bioscience is a psychedelic-based biotechnology company developing its proprietary neuromodulator pipeline to target cognitive, mood, and addiction disorders. Psilera leverages research strengths with executives from the pharmaceutical and cannabis industries to repurpose psychoactive natural products as building blocks for next generation therapies to improve mental health.

Share article on social media or email:

OrthoColorado Hospital, Porter Adventist Hospital, and Sky Ridge Medical Center have the best value outcomes for Hip and Knee Replacement in Denver, CO


best value outcomes for Hip and Knee Replacement in Denver, CO

“Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalization, rehospitalization, home health, nursing home, and ED costs.”

Dexur’s analysis of Medicare claims of hospitals within a 25-mile radius of Denver, Colorado, showed that OrthoColorado Hospital, Porter Adventist Hospital, and Sky Ridge Medical Center had the best value outcomes over a 90-day episode for Hip & Knee Replacement. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. The total cost of care data helps patients make appropriate choices and helps local ACOs such as Community Health Provider Alliance, Boulder Valley Care Network, LLC, and Banner Network Colorado, LLC, make appropriate referrals choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 470: Major Joint Replacement Or Reattachment Of Lower Extremity Without Major Complication Or Comorbidity (MCC), to adjust for complications and comorbidities.

OrthoColorado Hospital’s total cost of care over a 90-day episode was $16,205 (for the period between July 2016 to June 2019). The index hospitalization cost was $13,363 and the average rehospitalization cost was $1,140. The cost per rehospitalization was at an average of $14,756. Meanwhile, the average ED costs per hospitalization (when ED is involved) was $839.

Porter Adventist Hospital’s total cost of care over a 90-day episode was $16,579 (for the period of July 2016 to June 2019). The index hospitalization cost was $14,179 and the average rehospitalization cost was $1,054. The cost per rehospitalization was at an average of $19,740. Meanwhile, the average ED costs per hospitalization (when ED is involved) was $812.

Sky Ridge Medical Center’s total cost of care over a 90-day episode was $18,473 (for the period of July 2016 to June 2019). The index hospitalization cost was $13,886 and the average rehospitalization cost was $1,963. The cost per rehospitalization was at an average of $17,756. Meanwhile, the average ED costs per hospitalization (when ED is involved) was $686.

Share article on social media or email:

Final Entry Deadline Approaching in The 17th International Business Awards®


IBA final deadline approaching

New this year are a variety of COVID-19 response awards categories that do not have entry fees. These aim to honor heroes of every industry including medical, education, and more.

The IBAs feature more than 40 categories that do not require the payment of entry fees, including all 35 of the Company/Organization of the Year categories, and that there are many new and revised features of the IBAs for 2020.

The final entry deadline for the 2020 (17th annual) edition of The International Business Awards® is Tuesday, July 28.

The International Business Awards are widely considered to be the world’s premier business awards competition. In 2019 the competition attracted more than 4,000 nominations from organizations in more than 70 nations.

All individuals and organizations worldwide—public and private, for-profit and non-profit, large and small—may submit nominations to The International Business Awards. The final entry deadline this year is Tuesday, July 28. Entry details are available at http://www.StevieAwards.com/IBA.

Juries featuring more than 150 executives will determine the Stevie Award winners. The Gold, Silver, and Bronze Stevie Award winners will be announced on September 9. Stevie Award winners will be honored at a virtual awards ceremony this year.

New this year are a variety of COVID-19 response awards categories that do not have entry fees. These aim to honor heroes of every industry including medical, education, food delivery, media, public service, business response, and more.

The International Business Awards recognize achievement in every facet of the workplace. Categories include:

  • Management Awards
  • Entrepreneur of the Year Awards
  • Company of the Year Awards
  • Customer Service Awards
  • Human Resources Awards
  • Information Technology Awards
  • Marketing Awards
  • New Product Awards
  • Public Relations Awards
  • Web Site Awards, Smartphone and Tablet App, and other media awards

The IBAs feature more than 40 categories that do not require the payment of entry fees, including all 35 of the Company/Organization of the Year categories, and that there are many new and revised features of the IBAs for 2020, including:

  • Nine new categories to recognize singular business achievements in areas such as business turnaround, finance, revenue generation, and science and technology, among others.
  • The simplification of submission requirements in the Company/Organization, Corporate Communications & Public Relations, Marketing, and New Product & Product Management category groups.

About the Stevie Awards

Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, the Stevie Awards for Sales & Customer Service, and the new Middle East Stevie Awards. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Share article on social media or email:

Accreditation Council for Genetic Counseling Appoints New Leadership


News Image

The Board is extremely pleased to welcome the new officers and new board members and looks forward to continuing to improve accreditation processes for ACGC and grow the number of accredited programs in the field.

The Accreditation Council for Genetic Counseling is pleased to announce the results of its organizational leadership elections. Dawn C. Allain, MS, CGC, was elected to serve as President. Ms. Allain is the Director of the Genetic Counseling Graduate Program at The Ohio State University. She joined the board in 2017 and has been instrumental in furthering the organization’s mission to establish standards for graduate level genetic counseling education, evaluating educational programs to ensure compliance with those standards and protect the interest of the students, public and the integrity of the genetic counseling profession. Ms. Allain has served as the Program Review Committee chair prior to being elected President. Janet Williams, MS, CGC who has spent the last year as President, will become the Immediate Past President on the Board of Directors. Heather Creswick, MS, LCGC, who joined the board in 2017, will be ACGC’s next Treasurer. Molly McGinniss, MS, LCGC will be the next Program Review Committee Chair.

In addition, Erin Carmany, MS, Clinician Educator at the Center for Molecular Medicine and Genetics, Genetic Counseling Graduate Program at Wayne State University was elected to serve as on the ACGC Board of Directors and will begin her three year term. Ms. Carmany has been a practicing genetic counselor for over 20 years and earned her Master’s in Genetic Counseling in 1997 at the University of Colorado.

Sarah McBrien PhD, Assistant Professor and Director of Curricular & Learning Assessment at the University of Nebraska Medical Center College of Allied Health Professions was also elected to serve on the ACGC Board of Directors. Ms. McBrien develops and teaches in the Master of Health Professions Teaching and Technology program. She earned her Doctor of Philosophy in 2018 at the University of Nebraska-Lincoln.

The Board is extremely pleased to welcome the new officers and new board members and looks forward to continuing to improve accreditation processes for ACGC and grow the number of accredited programs in the field. The Board also wishes to acknowledge and thank the incredible contributions of Ian MacFarlane and Lori Williamson-Dean during their tenure on the Board.

All new positions begin in July 2020.

The Accreditation Council for Genetic Counseling (ACGC) is a specialized accrediting body newly formed in January 2013 out of its predecessor organization the American Board of Genetic Counseling. The ACGC’s mission is to:

  • Establish standards for graduate level genetic counseling education
  • Evaluate educational programs to ensure compliance with those standards
  • Protect the interest of the students, public and the integrity of the genetic counseling profession.


For more information about the Accreditation Council for Genetic Counseling please visit http://www.gceducation.org.

Share article on social media or email:

Catalent Completes Purchase of Pharmaceutical Packaging Facility in Shiga, Japan


Catalent's new pharmaceutical packaging facility in Shiga, Japan

Catalent’s new pharmaceutical packaging facility in Shiga, Japan

Catalent, a global leader in clinical supply services, today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

Operating in partnership with the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving both local customers, and global biotech and pharmaceutical companies. The facility will play an important role in Catalent’s expanding Asia-Pacific network, working alongside two sites in China and one in Singapore to ensure customers’ clinical trials are well-served across the region.

The facility will offer extensive clinical supply services including access to Catalent’s FastChain® demand-led supply services, primary and secondary packaging capabilities, a range of temperature options for storage and distribution, as well as clinical returns and destruction services.

For more information on Catalent’s clinical supply capabilities visit https://www.clinical.catalent.com.

About Catalent Clinical Supply Services

Catalent is a global leader in clinical supply services, with comprehensive and flexible solutions for small molecules, biologics, and cell and gene therapies and integrated solutions to accelerate speed to clinic. Catalent offers a full range services including clinical supply management, comprehensive packaging solutions, comparator sourcing, cold chain storage and global distribution and specialized supply chain services including direct-to-patient and demand-led supply. With nine GMP clinical packaging facilities and over 50 strategically located depots on six continents combined with more than 25 years’ experience across thousands of studies in more than 80 countries, Catalent has the comprehensive services, global scale and expertise necessary to reliably supply clinical trials of all sizes and complexity anywhere in the world.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including approximately 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

EZLynx Partners with Clearent to Offer Secure Online Payment Processing for Independent Insurance Agencies and Their Clients


EZLynx is proud to announce that it has partnered with Clearent to offer secure online payment processing for independent insurance agencies. Insureds can remit payments via credit card or eCheck easily and securely within EZLynx Client Center.

This new integration provides a simple way for agents to collect electronic payments from their clients. With current restrictions on travel and face-to-face meetings, providing a remote, contactless form of payment is particularly important. This added functionality to EZLynx Client Center eliminates the need for clients to visit the agent’s office or provide their credit card information over the phone. Electronic payment is also a safer, more efficient alternative to paper checks.

“Especially now, insureds need online options for the payment process, both paying from home and deferring payments,” said EZLynx Product Manager, Derek Armentrout. “Our partnership with Clearent makes it simple for agents to provide these alternatives.”

The industry trend toward customer self-service has never been more pressing, and the addition of payment processing to the EZLynx ONE PLATFORM answers this call.

“It is imperative that insurance customers have the ability to make payments with flexibility. That’s why we are excited to announce our partnership with EZLynx,” said Clearent Vice President of Partner Solutions, Doug Bernier. “Through a single integration, EZLynx’s customers will be able to safely and securely take payments online right within the EZLynx platform.”

Clearent is the latest addition to the EZLynx Connect platform. EZLynx Connect provides third-party businesses an avenue to distribute their products and services directly within the EZLynx platform. We’ve opened the EZLynx framework and invited carriers and vendors to work side-by-side with our technologists to innovate and integrate solutions to better the agency workflow.

About EZLynx

EZLynx is one of the leading software solutions for independent insurance agencies. In 2003, EZLynx pioneered real-time rating, enabling agents to generate quotes from multiple insurance carriers with a single data entry point. EZLynx has continued to create innovative software solutions that transform every facet of agency life, including agency management, client self-servicing, sales pipeline management, marketing and communications, accounting, eSignature, and more, all available on a unified, one platform solution. Over 20,000 agencies rely on EZLynx to provide more than 4 million home, auto, and package transactions every month. Learn more at EZLynx.com.

About Clearent

Clearent is a full-service payment-solutions provider with more than 600 employees, 50,000 customers, and $20 billion in payment processing volume. Clearent helps small- and medium-sized business owners securely accept payments anywhere with no hidden fees and transparent pricing. Headquartered in St. Louis, the company has been named to several prestigious lists year after year, including the Inc. 5000 list of fastest-growing companies, The Nilson Report’s list of top U.S. merchant acquirers, and The St. Louis Post-Dispatch Top Workplaces award. To learn more, visit clearent.com.

Share article on social media or email:

UH Ahuja Medical Center, Southwest General Health Center, and Lutheran Hospital have the best value outcomes for Hip and Knee Replacement in Cleveland, Ohio


best value outcomes for Hip and Knee Replacement in Cleveland, Ohio

“Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalization, rehospitalization, home health, nursing home, and ED costs.”

Dexur’s analysis of medicare claims of hospitals within a 25-mile radius of Cleveland, Ohio, showed that University Hospitals Ahuja Medical Center, Southwest General Health Center, and Lutheran Hospital had the best value outcomes over a 90 day episode for Hip & Knee replacement. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. Total cost of care helps patients make appropriate choices and helps local ACOs, such as Cleveland Clinic Medicare ACO, LLC, University Hospitals Coordinated Care Organization, and MetroHealth Care Partners, make appropriate referral choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 470: Major Joint Replacement Or Reattachment Of Lower Extremity Without Major Complication Or Comorbidity (MCC), to adjust for complications and comorbidities.

University Hospitals Ahuja Medical Center’s total cost of care over a 90 day episode was $16,868 (for the period between July 2016 and June 2019). The index hospitalization cost was $11,400 and the average rehospitalization cost per hospitalization was $1,223. The cost per rehospitalization was at an average of $15,768. Meanwhile, the average ED costs per hospitalization (when ED is involved) was $805.

Southwest General Health Center’s total cost of care over a 90 day episode was $16,967 (for the period between July 2016 and June 2019). The index hospitalization cost was $12,263 and the average rehospitalization cost per hospitalization was $1,244. The cost per rehospitalization was at an average of $16,701. Meanwhile, the average ED costs per hospitalization (when ED is involved) was $900.

Lutheran Hospital’s total cost of care over a 90 day episode was $17,089 (for the period between July 2016 and June 2019). The index hospitalization cost was $12,394 and the average rehospitalization cost per hospitalization was $1,089. The cost per rehospitalization was at an average of $14,936. Meanwhile, the average ED costs per hospitalization (when ED is involved) was $664.

Share article on social media or email:

Recognized Diversity Leader Beverly Jennings Launches SEE Company


News Image

Beverly Jennings, Founder & CEO, SEE Company

SEE Company enables diversity-forward and inclusion-focused enterprises to achieve significant growth. Our vision is to ‘see everyone elevate.’

Beverly Jennings, former Head of Global Supplier Diversity & Inclusion at Johnson & Johnson, has launched SEE Company to enable diversity-forward and inclusion-focused enterprises to achieve significant growth.

As Founder and CEO, Jennings brings her C-level business knowledge, values-driven leadership and supplier diversity expertise to corporations and business owners, preparing them to succeed in an ever-changing environment.

With her signature approach and energy, Jennings is leading SEE Company with her vision to “see everyone elevate.” As a trusted advisor and certified business coach, she offers strategies and guidance for executives to deliver measurable success. Her three decades of experience span customer service, process excellence, end-to-end supply chain management and business development.

Jennings also extends her knowledge to Boards of growth-oriented organizations. She is Vice Chair and Executive Committee member of the Billion Dollar Roundtable (BDR), a non-profit of companies spending $1 billion or more annually with diverse suppliers, which J&J joined as the first healthcare company. She co-chairs the BDR Global Committee and leads the BDR Triad, which connects corporations, diverse businesses and investors for growth.

She is a member of the Board of Directors for Turtle & Hughes, one of the largest independent electrical and industrial distributors in the nation, and serves on the Board of Rose International, one of the leading minority- and woman-owned providers of workforce and technology solutions.

Her previous role at J&J was Vice President, Worldwide Process Excellence, Consumer Group. Earlier, she was Director of Manufacturing at Vistakon, now Johnson & Johnson Vision Care, with responsibility for 1,200 employees. Prior to that she served in a variety of Director positions including Quality, Customer Service and Distribution. For eight years, she co-chaired the African American Leadership Council National Employee Resource Group with 35 chapters and 1,500 members. In addition to healthcare, Jennings’ management experience encompasses the retail and food industries.

Jennings previously served as a board member to the Healthcare Supplier Diversity Alliance, the Women Presidents’ Education Organization (WPEO), Women’s Business Enterprise National Council (WBENC), Community First Credit Union and the Girl Scouts of Gateway Council.

She has been recognized as a champion, sponsor, mentor and advocate for business and community. These include J&J’s Top 25 People of the Year, the Diverse Manufacturing Supply Chain Alliance (DMSCA) Legacy Award, the WBE Hall of Fame and a Top 25 Leading Women Entrepreneur (LWE) in New Jersey. She also received the WBENC Applause Award, the United Negro College Fund (UNCF) Masked Award, and was a Gateway Girl Scouts Woman of Distinction.

Jennings holds an MBA in Industrial Management from the University of Dallas; she is a Certified Master Business Coach from Fowler School of Business, and she earned a BS degree in Management from the University of West Florida.

For more information, visit http://seecompany.co

Share article on social media or email:

Finally! A Solution to Access Patient Data During Downtimes


News Image

During a system downtime, if our patient needs blood during a surgical procedure, we need immediate access to determine their blood type,” explains the Lead Applications Analyst for the health system.

Interbit Data, a leading technology company providing care teams with on-demand access to crucial patient data, will host a webinar on Tuesday, July 28, to share how hospitals can retain access to patient information in the event of system downtimes, regardless of their EMR.

Interbit Data’s NetSafe is an automated software solution that ensures uninterrupted, HIPAA-compliant access to patient data during system downtimes, including planned updates, power outages, natural disasters, and cyberattacks.

“System downtimes occur for a multitude of reasons,” says Arthur Young, President and CEO of Interbit Data. “When they do, it’s our job to make sure frontline caregivers still have accurate, secure information at their fingertips to make the real-time treatment decisions that keep patients safe.”

The webinar will highlight a case study from a midwest health system that – once they switched EMRs – could not access critical information for some of their applications and departments, because those applications were not linked with the new EMR. As a result, the health system had no way to access vital blood bank data during system downtimes, a lapse that could compromise patient safety and even risk lives.

“During a system downtime, if our patient needs blood during a surgical procedure, we need immediate access to determine their blood type,” explains the Lead Applications Analyst for the health system.

Hospital and health systems, healthcare IT vendors and members of the media are invited to attend the webinar to discover:


  • How to ensure access to data during downtimes
  • Why EMR downtime solutions may be insufficient
  • How automated report distribution can save crucial time and resources

Webinar: Finally! A Solution to Access Patient Data During Downtimes 

Date: Tuesday, July 28, 2020

Time: 1:00 – 1:45 pm ET

Register Here

About Interbit Data

Interbit Data is an industry leader in data accessibility for hospitals and health systems. Our software solutions ensure secure, reliable access to patient information anytime, anywhere – including at offsite locations, during system downtimes, and even during cyberattacks. With 23+ years in business and more than 700 customers across North America, we are experts at data access and report distribution, empowering you to improve efficiency, streamline workflows, provide optimal patient service and high-quality care, all while meeting federal patient privacy and access requirements. Discover more at interbitdata.com.

Share article on social media or email: